| Before matching | After matching | |||||
---|---|---|---|---|---|---|---|
Overall Population | Staged surgery | Simultaneous resection | P | Staged surgery | Simultaneous resection | P | |
N (%) | 70 (100) | 48 (69) | 22 (31) | - | 22 (50) | 22 (50) | - |
Oncological results | Â | ||||||
Adjuvant chemotherapy, n (%) | 56 (80) | 38 (79.1) | 18 (32.1) | 1.000 | 7 (31.8) | 6 (27.3) | 0.741 |
Recurrence, n (%) | 51 (72.9) | 40 (83.3) | 11 (50) | 0.0078 | 18 (81.8) | 11 (50) | 0.026 |
Rectal | 5 (7.1) | 5 (10.4) | 0 | 0.1727 | 2 (9.1) | 0 | 0.148 |
Liver | 32 (45.7) | 26 (54.2) | 6 (27.2) | 0.0425 | 14 (63.6) | 8 (36.6) | 0.070 |
Carcinosis | 11 (15.7) | 8 (16.7) | 3 (13.6) | 1.000 | 2 (9.1) | 3 (13.6) | 0.635 |
Number of recurrences sites, n (%) | Â | ||||||
1 | 36 (51.4) | 26 (54.2) | 10 (45.5) | 0.5604 | 16 (88.9) | 10 (90.9) | 0.862 |
2 | 8 (11.4) | 7 (14.6) | 1 (4.5) | 2 (11.1) | 1 (9.1) | ||
3 | 1 (1.4) | 1 (2.1) | 0 | 0 | 0 | ||
Time to recurrence (month), median ± IQR | 15 (11–20) | 17 (11–21) | 13 (11–14) | 0.3568 | 13 (6–25) | 8 (5–11) | 0.465 |
Median of follow up (months) ± IQR | 28 (18–39) | 28 (19–42) | 20 (13–34) | 0.0990 | 28 (16–38) | 16 (8–38) | 0.285 |
Overall survival at 3Â years (%) | 86% | 85% | 42% | 0.0749 | 68% | 62% | 0.517 |
Overall survival at 5Â years (%) | 44% | 77% | 54% | 45% | 46% | ||
Disease free survival at 3Â years (%) | 20% | 19% | 4.5% | 0.6851 | 7% | 10% | 0.691 |
Disease free survival at 5 years (%) | 3.5% | 24% | 0% | – | – | ||
Recurrence treatment, n (%) | Â | ||||||
Surgery | 11 (15.7) | 9 (18.8) | 2 (9.1) | 0.2998 | 6 (27.3) | 2 (9.1) | 0.118 |
Chemotherapy | 39 (55.7) | 31 (64.6) | 8 (36.4) | 0.7063 | 13 (59.1) | 8 (36.4) | 0.131 |
Radiotherapy | 11 (15.7) | 7 (14.6) | 4 (18.2) | 0.2220 | 3 (13.6) | 4 (18.2) | 0.680 |
Delayed fistula, n (%) | 2 (2.9) | 0 | 2 (9.1) | 0.0431 | 0 | 0 | - |